SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway

Item

http://www.wikidata.org/entity/Q37252312

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

SPIB is a novel prognostic fac ...... tosis via the PI3K-AKT pathway

@en

SPIB is a novel prognostic fac ...... osis via the PI3K-AKT pathway.

@nl

type

Item

label

SPIB is a novel prognostic fac ...... tosis via the PI3K-AKT pathway

@en

SPIB is a novel prognostic fac ...... osis via the PI3K-AKT pathway.

@nl

prefLabel

SPIB is a novel prognostic fac ...... tosis via the PI3K-AKT pathway

@en

SPIB is a novel prognostic fac ...... osis via the PI3K-AKT pathway.

@nl

P1476

SPIB is a novel prognostic fac ...... tosis via the PI3K-AKT pathway

@en

P2093

Akihiro Tomita

http://www.w3.org/2001/XMLSchema#string

Fumihiko Hayakawa

http://www.w3.org/2001/XMLSchema#string

Hitoshi Kiyoi

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Shimada

http://www.w3.org/2001/XMLSchema#string

Satoko Shimada

http://www.w3.org/2001/XMLSchema#string

Shigeo Nakamura

http://www.w3.org/2001/XMLSchema#string

Tomoki Naoe

http://www.w3.org/2001/XMLSchema#string

P2860

The ETS transcription factor Spi-B is required for human plasmacytoid dendritic cell development

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.

P304

1270-1280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.13001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Akihiko Sakamoto

Yusuke Takagi

P577

2016-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27348272

http://www.w3.org/2001/XMLSchema#string

P932

5021043

http://www.w3.org/2001/XMLSchema#string